Table 4 Factors associated with the development of antibody-mediated rejection within 1 year after kidney transplantation in blood type O recipients.

From: Impact of IgG monitoring and machine learning based prediction on outcomes of ABO incompatible kidney transplantation in blood type O recipients

Variables

Univariate analysis

Multivariate analysis

OR (95% CI)

p-value

OR (95% CI)

p-value

Age, years

1.04 (1.00–1.10)

0.05

N/A

N/A

Female vs. Male

3.77 (0.85–16.75)

0.042

2.61 (1.06–6.40)

0.036

HLA-A, -B, -DR mismatch

1.09 (0.79–1.49)

0.59

N/A

N/A

PRA class I

0.90 (0.75–1.08)

0.28

N/A

N/A

PRA class II

0.97 (0.92–1.02)

0.26

N/A

N/A

Tacrolimus vs. cyclosporin

0.71 (0.32–9.23)

0.53

N/A

N/A

Rituximab dose, mg

1.00 (0.99 – 1.02)

0.51

N/A

N/A

IgG vs. IgM monitoring

0.23 (0.05–1.06)

0.06

0.35 (0.14–0.87)

0.024

Initial IgM anti-ABO titer

(/2n)

1.20 (0.98–1.48)

0.077

1.25 (1.01–1.55)

0.034

Preoperative plasmapheresis number

1.07 (0.85–1.34)

0.56

N/A

N/A

  1. HLA, Human Leukocyte Antigen; PRA, panel reactive antibody; IgM, Immunoglobulin M; IgG, Immunoglobulin G.
Back to article page